
    
      This randomised, multi-center, controlled trial is designed to assess the efficacy and safety
      of icotinib with concurrent radiotherapy versus etoposide/cisplatin with concurrent
      radiotherapy in stage III non-small cell lung cancer with EGFR 19/21 Mutation, the primary
      endpoint is progression-free survival
    
  